Day: May 6, 2021

H1 2020/21Interim financial results, H1 2020/21(1 October 2020 – 31 March 2021) Organic growth guidance maintained at 7-8% and EBIT margin guidance before special items raised from 31-32% to 32-33%.Coloplast delivered 2% organic growth in Q2. Reported revenue in DKK was down by 1% to DKK 4,753 million. Year to date organic growth was 4% and reported revenue in DKK was flat at DKK 9,491 million due to significant FX headwinds. Organic growth rates by business area year to date: Ostomy Care 5%, Continence Care 3%, Interventional Urology 4% and Wound & Skin Care 1%. The Chronic Care business in Q2 was negatively impacted by around DKK 150 million in stock building in the comparison period and lower growth in new patients in Europe due to COVID-19, in particular in the UK. Ostomy Care delivered 4% organic growth in Q2 lifted by...

Revenue increased 17.5% to $1,027 million. Organic revenue increased 12.1% GAAP EPS increased to $0.53 vs loss of ($0.63) in 2020 Non-GAAP EPS increased 67.4% to $0.72 vs $0.43 in 2020 GAAP operating income increased to $154 million vs loss of ($125) million in 2020 Non-GAAP operating income increased 67.2% to $219 million vs $131 million in 2020 Operating cash flows increased to $49 million vs loss of ($10) million in 2020 Raises FY21 Non-GAAP EPS outlook to $2.75 to $2.90 from $2.60 to $2.80CHARLOTTE, N.C., May 06, 2021 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY), The Dental Solutions Company, today announced its financial results for the first quarter of 2021. First quarter net sales of $1,027 million increased 17.5%, compared to $874 million in the first quarter...

PORTSMOUTH, N.H., May 06, 2021 (GLOBE NEWSWIRE) — Sprague Resources LP (“Sprague”) (NYSE: SRLP) today reported its financial results for the first quarter ended March 31, 2021. First Quarter 2021 HighlightsNet sales were $1,036.1 million for the first quarter of 2021, compared to net sales of $959.9 million for the first quarter of 2020. GAAP net income was $48.8 million for the first quarter of 2021, compared to net income of $46.7 million for the first quarter of 2020. Adjusted gross margin* was $106.2 million for the first quarter of 2021, compared to adjusted gross margin of $83.1 million for the first quarter of 2020. Adjusted EBITDA* was $61.8 million for the first quarter of 2021, compared to adjusted EBITDA of $42.4 million for the first quarter of 2020.“Sprague’s Adjusted EBITDA increased by 46% over last year as our...

Company Q1 2021 Revenues, Gross Margin and EPS all Exceed Guidance; Revenues, Gross Margin and EPS All Meet Its Pre-Announced Key Financial Results and Reached Record Highs Provides Q2 2021 Guidance: Revenues to Increase by 15%-20% sequentially, Gross Margin is expected to be 45.5%-47.5%, IFRS profit per Diluted ADS to be 54.0 Cents to 60.0 Cents, and Non-IFRS profit per Diluted ADS to be 54.2 Cents to 60.2 CentsRevenues, gross margin and EPS all reached all-time highs in Q1 2021 Q1 revenues increased 12.1% QoQ to $309.0M, exceeding the guidance of an increase of around 5-10% Strong demands across all major business segments in Q1 Product sales: large driver ICs, 22.6% of revenues, up 8.8% QoQ; small and medium-sized driver ICs, 66.1% of revenues, up 14.7% QoQ; non-driver products, 11.3% of revenues, up 4.0% QoQ Q1 gross margin reached...

– TEAD Inhibition Represents an Emerging Approach for Addressing Multiple Biomarker-Defined Cancers Characterized by Aberrant Hippo Pathway Signaling, which is Genetically Altered in up to 10% of Cancers – – SpringWorks Expects to Nominate a Development Candidate and Commence IND-Enabling Studies in 2022 – STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has entered into an exclusive worldwide license agreement with Katholieke Universiteit Leuven (KU Leuven) and the Flanders Institute for Biotechnology (VIB) for the in-license of a portfolio of novel small molecule inhibitors of the TEA Domain (TEAD)...

Organic growth in Q2 was adversely impacted by the COVID-19 pandemic as well as DKK 150 million in stock building in primarily Europe in Q2 last year. EBIT increased by 2% to 1,577m corresponding to an EBIT margin of 33% before special items. The company maintains full-year organic growth guidance at 7-8% and raises expectations for the EBIT margin from 31-32% to 32-33% before special items. The company reported 2% organic growth in Q2. Reported revenue in DKK was down by 1% to DKK 4,753 million, impacted by the depreciation of the USD and a number of Emerging markets currencies against DKK. The EBIT margin was 33% before special items against 32% last year, which reflects continued strong cost control during the COVID-19 pandemic as well as sustained investments in growth opportunities and innovation. EBIT was impacted by a further DKK...

H1 2020/21Interim financial results, H1 2020/21(1 October 2020 – 31 March 2021) Organic growth guidance maintained at 7-8% and EBIT margin guidance before special items raised from 31-32% to 32-33%.Coloplast delivered 2% organic growth in Q2. Reported revenue in DKK was down by 1% to DKK 4,753 million. Year to date organic growth was 4% and reported revenue in DKK was flat at DKK 9,491 million due to significant FX headwinds. Organic growth rates by business area year to date: Ostomy Care 5%, Continence Care 3%, Interventional Urology 4% and Wound & Skin Care 1%. The Chronic Care business in Q2 was negatively impacted by around DKK 150 million in stock building in the comparison period and lower growth in new patients in Europe due to COVID-19, in particular in the UK. Ostomy Care delivered 4% organic growth in Q2 lifted by...

Thursday, Schouw & Co. released its interim report for the first quarter of 2021; strong Q1 performance with revenue and EBITDA improving. HighlightsStrong Q1 performance with revenue and EBITDA improving Return on invested capital (excluding goodwill) at a solid 15.9% After the end of the quarter, Borg Automotive agreed to acquire SBS Automotive Raising guidance for full-year revenue of about DKK 22.5 billion and EBITDA in the DKK 2,105-2,315 million range due to Fibertex Nonwovens, GPV, HydraSpecma and Borg Automotive.Statement by Jens Bjerg Sørensen, President of Schouw & Co. “Schouw & Co. is off to a very good start to 2021, reporting growth in both revenue and earnings. We are seeing the positive effects of previous years’ investments in capacity and innovation, and we have a strong platform for sustained value...

Press releaseParis, 6 May 2021 NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION WOULD BE ILLEGAL Announcement of the final results of the public takeover bid for Orange Belgium (the “Offer”) Following the voluntary reopening of the Offer, which began on April 28 and ended on May 4, 14,368,307 Orange Belgium shares in total were tendered to the Offer, representing 23.94% of the share capital of Orange Belgium and 50.97% of the total number of shares targeted by the Offer. Payment of the Offer price for the shares tendered during the reopening of the Offer will take place on May 17. On this date, Orange SA will directly and indirectly hold 46,191,064 shares of Orange Belgium (including treasury shares), representing 76.97% of the share capital...